1. Home
  2. RACE vs REGN Comparison

RACE vs REGN Comparison

Compare RACE & REGN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Ferrari N.V.

RACE

Ferrari N.V.

HOLD

Current Price

$346.56

Market Cap

61.6B

ML Signal

HOLD

Logo Regeneron Pharmaceuticals Inc.

REGN

Regeneron Pharmaceuticals Inc.

HOLD

Current Price

$601.27

Market Cap

73.2B

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RACE
REGN
Founded
1947
1988
Country
Italy
United States
Employees
N/A
N/A
Industry
Auto Manufacturing
Biotechnology: Pharmaceutical Preparations
Sector
Consumer Discretionary
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
61.6B
73.2B
IPO Year
2015
1995

Fundamental Metrics

Financial Performance
Metric
RACE
REGN
Price
$346.56
$601.27
Analyst Decision
Strong Buy
Buy
Analyst Count
9
25
Target Price
$477.86
$830.16
AVG Volume (30 Days)
675.6K
1.1M
Earning Date
05-05-2026
04-29-2026
Dividend Yield
1.26%
0.55%
EPS Growth
N/A
8.19
EPS
N/A
6.75
Revenue
N/A
$5,872,227,000.00
Revenue This Year
$7.91
$12.45
Revenue Next Year
$7.51
$10.13
P/E Ratio
$34.59
$91.29
Revenue Growth
N/A
20.82
52 Week Low
$312.51
$503.25
52 Week High
$519.10
$821.11

Technical Indicators

Market Signals
Indicator
RACE
REGN
Relative Strength Index (RSI) 52.32 33.50
Support Level $322.01 $591.52
Resistance Level $357.77 $618.01
Average True Range (ATR) 8.09 15.52
MACD 1.56 1.36
Stochastic Oscillator 59.06 19.12

Price Performance

Historical Comparison
RACE
REGN

About RACE Ferrari N.V.

Ferrari designs, engineers, and manufactures some of the world's most expensive luxury cars. With supply carefully controlled to be below demand and a brand steeped in decades of motor racing history, a Ferrari is viewed as a status symbol. In 2025, the company sold 13,640 vehicles at an average price over EUR 520,000 with more than 80% of its vehicles being sold to existing Ferrari clients. Eighty-four percent of revenue is generated from the sale of cars and spare parts and 10% from sponsorship, commercial, and brand activities including racing and lifestyle activities. In 2025, the Europe, Middle East, and Africa region accounted for 49% of revenue, the Americas was 32%, mainland China, Hong Kong, and Taiwan was 7%, and the rest of Asia was 12%.

About REGN Regeneron Pharmaceuticals Inc.

Regeneron Pharmaceuticals discovers, develops, and commercializes products that fight eye disease, cardiovascular disease, cancer, and inflammation. The company has several marketed products, including low-dose Eylea and Eylea HD, approved for wet age-related macular degeneration and other eye diseases; Dupixent in immunology; Praluent for LDL cholesterol lowering; Libtayo in oncology; Kevzara in rheumatoid arthritis; and Lynozyfic for multiple myeloma. Regeneron has multiple partnerships and collaboration agreements, with Sanofi (Dupixent, others) and Bayer (Eylea) as its largest partners.

Share on Social Networks: